What is the difference between KRAS G12D and KRAS G12C
According to the National Cancer Institute (NCI), KRAS mutations occur when there are changes in the KRAS gene, which produces proteins involved in cell signaling. The specific location of these mutations (G12D vs G12C) affects both prognosis and treatment options.
Key differences:
-
Molecular Structure: According to ASCO guidelines, KRAS G12C involves a substitution of glycine with cysteine at position 12, while KRAS G12D involves a substitution of glycine with aspartic acid at the same position. This molecular difference is crucial because it affects how drugs can target these mutations.
-
Treatment Options: The FDA has approved specific treatments for KRAS G12C mutations, including:
- Sotorasib (Lumakras) - approved in 2021 for KRAS G12C-mutated non-small cell lung cancer
- Adagrasib (Krazati) - also approved for KRAS G12C-mutated NSCLC
According to NCCN Guidelines, while KRAS G12C has targeted therapy options, KRAS G12D currently does not have FDA-approved targeted treatments. Patients with G12D mutations typically receive standard therapy options for their cancer type.
- Frequency: The NCI notes that G12D mutations are more commonly found in pancreatic cancer, while G12C mutations are more frequently observed in lung cancer.
Always consult with your oncologist about your specific mutation and treatment options, as research in this field is rapidly evolving.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 28, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about General
- What is the difference between phase 1, 2, and 3 cancer clinical trials
- What is the difference between a CT scan and a PET scan
- What is the difference between a somatic mutation and a germline mutation
- What is the difference between a primary tumor and a metastasis
- What is the difference between benign and malignant tumors
- What is the difference between immunohistochemistry (IHC) and FISH testing
- Me about each of the Common personalized medicine tests (), some of the differences between them, and how we should...
- We have a report that contains the g12d mutation. If we have that knowledge does that mean ngs was done? Or would...